Total Funding
28
11
Total FundingSeries B raised
Growth Score
-1 pts
Heat Score
8 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
456576
At Akarna, our mission is to develop best-in-class treatments for NASH and other chronic liver diseases
- Christopher Krueger: Chief Business OfficerPast Role: Xceptor, Senior Executive
- Raju Mohan: Co-Founder & CEOPast Role: Oppilan Pharma, Founder & Director
About the Company
Akarna Therapeutics is a biopharmaceutical company with offices in San Diego and Cambridge (UK) that is developing novel small molecule therapeutics that target inflammatory and fibrotic diseases. Our lead program is a non-bile acid FXR agonist that is potentially a best-in-class therapeutic for the treatment of nonalcoholic steatohepatitis (NASH),
a progressive form of fatty-liver disease for which there are no approved therapies. Akarna’s lead candidate is currently in preclinical, IND-enabling toxicology and safety pharmacology studies with first-in-human studies planned for early 2017.
